Development of novel immune interventions for prostate cancer

Clinical Genitourinary Cancer

Volumn 10, Issue 2, 2012, Pages 84-92

  Agarwal, Neeraj ^a   Padmanabh, Sumanth ^a   Vogelzang, Nicholas J ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Immune checkpoints blockade; Immunotherapy; Prostate cancer; Vaccine therapy

Indexed keywords

AP 1903; BPX 101; CANCER VACCINE; CV 9103; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; IPILIMUMAB; MKC 1106 PP; PEPTIDE VACCINE; RNA VACCINE; SIPULEUCEL T; TICILIMUMAB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL EXPANSION; CHILL; DERMATITIS; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; ENTEROCOLITIS; FATIGUE; FEVER; GLEASON SCORE; HUMAN; HYPOPHYSITIS; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; NAUSEA; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84862107423     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.01.012     Document Type: Review

References (73)

1. A. Iwasaki, R. Medzhitov Regulation of adaptive immunity by the innate immune system Science 327 2010 291 295
2. J.E. Smith-Garvin, G.A. Koretzky, M.S. Jordan T cell activation Annu Rev Immunol 27 2009 591 619
3. A.M. Miller, P. Pisa Tumor escape mechanisms in prostate cancer Cancer Immunol Immunother 56 2007 81 87 (Pubitemid 44812449)
4. S. Kusmartsev, J. Vieweg Enhancing the efficacy of cancer vaccines in urologic oncology: new directions Nat Rev Urol 6 2009 540 549
5. Y.S. Barach, J.S. Lee, X. Zang T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics Trends Mol Med Oct 21, 2010 [E-pub ahead of print]
6. R.A. Blades, P.J. Keating, L.J. McWilliam Loss of HLA class I expression in prostate cancer: implications for immunotherapy Urology 46 1995 681 686 discussion 686-7
7. H. Zhang, J. Melamed, P. Wei Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer Cancer Immun 3 2003 2
8. M. Campoli, S. Ferrone Hla antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition Semin Immunopathol 33 2011 321 334
9. X. Filella, J. Alcover, M.A. Zarco Analysis of type T1 and T2 cytokines in patients with prostate cancer Prostate 44 2000 271 274
10. U. Elsässer-Beile, D. Gierschner, P. Jantscheff Different basal expression of type T1 and T2 cytokines in peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate Anticancer Res 23 2003 4027 4031 (Pubitemid 37474360)
11. A. Mantovani, P. Allavena, A. Sica Cancer-related inflammation Nature 454 2008 436 444
12. C. Murdoch, M. Muthana, S.B. Coffelt The role of myeloid cells in the promotion of tumour angiogenesis Nat Rev Cancer 8 2008 618 631
13. A. De Luca, N. Normanno Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors IDrugs 13 2010 636 645
14. H. Nishimura, T. Okazaki, Y. Tanaka Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice Science 291 2001 319 322 (Pubitemid 32096320)
15. X. Zang, J.P. Allison The B7 family and cancer therapy: costimulation and coinhibition Clin Cancer Res 13 2007 5271 5279 (Pubitemid 47510350)
16. X. Zang, R.H. Thompson, H.A. Al-Ahmadie B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome Proc Natl Acad Sci U S A 104 2007 19458 19463
17. G. Chavin, Y. Sheinin, P.L. Crispen Expression of immunosuppressive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases Clin Cancer Res 15 2009 2174 2180
18. L. Buonaguro, A. Petrizzo, M.L. Tornesello Translating tumor antigens into cancer vaccines Clin Vaccine Immunol 18 2011 23 34
19. + regulatory T cells in immunological tolerance to self and non-self Nat Immunol 6 2005 345 352 (Pubitemid 41716771)
20. A.H. Tien, L. Xu, C.D. Helgason Altered immunity accompanies disease progression in a mouse model of prostate dysplasia Cancer Res 65 2005 2947 2955 (Pubitemid 40490100)
21. J.T. Becker, B.M. Olson, L.E. Johnson DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer J Immunother 33 2010 639 647
22. D.L. Longo New therapies for castration-resistant prostate cancer N Engl J Med 363 2010 479 481
23. G. Sonpavde, K.M. Slawin, D.M. Spencer Emerging vaccine therapy approaches for prostate cancer Rev Urol 12 2010 25 34
24. + T cell responses in patients with metastatic prostate cancer J Immunol 174 2005 3798 3807 (Pubitemid 40354093)
25. E.J. Small, P. Fratesi, D.M. Reese Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J Clin Oncol 18 2000 3894 3903
26. P.W. Kantoff, C.S. Higano, N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
27. C.S. Higano, P.F. Schellhammer, E.J. Small Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670 3679
28. T.M. Beer, G.T. Bernstein, J.M. Corman Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer Clin Cancer Res 17 2011 4558 4567
29. An open label, phase 2 trial of immunotherapy with sipuleucel-T (Provenge®) as neoadjuvant treatment in men with localized prostate cancer http://www.Clinicaltrials.gov NCT00715104. Accessed: January 5, 2012
30. A pilot study to test the feasibility and immunologic impact of sipuleucel-T (Provenge) administered with or without anti-PD-1 mAb (CT-011) and low dose cyclophosphamide in men with advanced castrate-resistant prostate cancer http://www/Clinicaltrials.gov NCT01420965. Accessed: January 5, 2012
31. A randomized, open-label, phase 2 trial examining the sequencing of sipuleucel-T and androgen deprivation therapy in men with non-metastatic prostate cancer and a rising serum prostate specific antigen after primary therapy http://Clinicaltrials.gov NCT01431391. Accessed: January 5, 2012
32. K. Fizazi, T. Powles, D.J. George A randomized, controlled phase III global trial comparing sipuleucel-T T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer J Clin Oncol 29 suppl 2011 abstract TPS188
33. G. Sonpavde, N. Agarwal, T.K. Choueiri Recent advances in immunotherapy for the treatment of prostate cancer Expert Opin Biol Ther 11 2011 997 1009
34. K.M. Slawin, G. Sonpavde, J.D. McMannis Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol 29 suppl 2011 abstract 4670
35. L.J. Mu, J.A. Kyte, G. Kvalheim Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients Br J Cancer 93 2005 749 756 (Pubitemid 41486433)
36. A. Heiser, D. Coleman, J. Dannull Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors J Clin Invest 109 2002 409 417 (Pubitemid 34141815)
37. M. Vergati, C. Intrivici, N.Y. Huen Strategies for cancer vaccine development J Biomed Biotechnol July 11, 2010 [e-pub ahead of print]
38. C.G. Drake Prostate cancer as a model for tumour immunotherapy Nat Rev Immunol 10 2010 580 593
39. P.M. Arlen, H.L. Kaufman, R.S. DiPaola Pox viral vaccine approaches Semin Oncol 32 2005 549 555 (Pubitemid 41772682)
40. L.E. Harrington, RvR. Most, J.L. Whitton Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope J Virol 76 2002 3329 3337 (Pubitemid 34224535)
41. P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
42. A Trial of PROSTVAC/GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (Prospect) http://Clinicaltrials.gov NCT01322490. Accessed: January 5, 2012
43. S. Pasquini, Z. Xiang, Y. Wang Cytokines and costimulatory molecules as genetic adjuvants Immunol Cell Biol 75 1997 397 401 (Pubitemid 27408048)
44. R.M. Conry, D.T. Curiel, T.V. Strong Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients Clin Cancer Res 8 2002 2782 2787 (Pubitemid 35025720)
45. + T cells Nat Immunol 6 2005 593 599 (Pubitemid 41710730)
46. + T cell immune responses compared to intramuscular injection and intradermal gene gun delivery Vaccine 27 2009 5450 5459
47. D.G. McNeel, E.J. Dunphy, J.G. Davies Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer J Clin Oncol 27 2009 4047 4054
48. S. Pascolo Vaccination with messenger RNA Methods Mol Med 127 2006 23 40
49. H. Kübler, T. Maurer, A. Stenzl Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA J Clin Oncol 29 suppl 2011 abstract 4535
50. J.S. Weber, N.J. Vogelzang, M.S. Ernstoff A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors J Immunother 34 2011 556 567
51. G. Dranoff, E. Jaffee, A. Lazenby Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci U S A 90 1993 3539 3543 (Pubitemid 23111402)
52. Cell Genesys. Announces termination of VITAL-1 phase 3 Trial of GVAX Immunotherapy for Prostate Cancer [press release]. South San Francisco, CA: Cell Genesys, Inc.
53. K.C. Kaehler, S. Piel, E. Livingstone Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management Semin Oncol 37 2010 485 498
54. F.S. Hodi, S.J. O'Day, D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
55. L.F. Langer, T.M. Clay, M.A. Morse Update on anti-CTLA-4 antibodies in clinical trials Expert Opin Biol Ther 7 2007 1245 1256 (Pubitemid 47305249)
56. D. O'Mahony, J.C. Morris, C. Quinn A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clin Cancer Res 13 2007 958 964 (Pubitemid 46340373)
57. Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer http://Clinicaltrials.gov NCT01057810. Accessed: January 5, 2012
58. A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel http://Clinicaltrials. gov NCT00861614. Accessed: January 5, 2012
59. F. Hirano, K. Kaneko, H. Tamura Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 2005 1089 1096 (Pubitemid 40216472)
60. Y. Iwai, S. Terawaki, T. Honjo PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells Int Immunol 17 2005 133 144 (Pubitemid 40246578)
61. R.H. Thompson, M.D. Gillett, J.C. Cheville Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 101 2004 17174 17179 (Pubitemid 39627793)
62. J. Dannull, Z. Su, D. Rizzieri Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells J Clin Invest 115 2005 3623 3633 (Pubitemid 43121851)
63. + T cells: a common basis between tumor immunity and autoimmunity J Immunol 163 1999 5211 5218
64. R.P. Sutmuller, L.M. van Duivenvoorde, A. van Elsas Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses J Exp Med 194 2001 823 832 (Pubitemid 32983017)
65. A. Hoos, A.M. Eggermont, S. Janetzki Improved endpoints for cancer immunotherapy trials J Natl Cancer Inst 102 2010 1388 1397
66. E.J. Small, P.F. Schellhammer, C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094 (Pubitemid 46638945)
67. H.L. Kaufman, W. Wang, J. Manola Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group J Clin Oncol 22 2004 2122 2132 (Pubitemid 41095145)
68. R.A. Madan, J.L. Gulley, J. Schlom Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy Clin Cancer Res 14 2008 4526 4531
69. L. Fong, S.S. Kwek, S. O'Brien Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF Cancer Res 69 2009 609 615
70. E.J. Small, N.S. Tchekmedyian, B.I. Rini A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 2007 1810 1815 (Pubitemid 46952950)
71. M.K. Tollefson, R.J. Karnes, R.H. Thompson A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer 2010 Genitourinary Cancers Symposium. 2010; abstract 168 http://www.asco.org/ascov2/Meetings/Abstracts?&vmview= abst-detail-view&confID=73&abstractID=30897 Accessed: February 10, 2012
72. S.F. Slovin, T.M. Beer, C.S. Higano Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol 27 suppl 2009 15s
73. W. Gerritsen, A.J. van den Eertwegh, T. de Gruijl Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) J Clin Oncol 26 suppl 2008 abstract 5146